The article compares Amgen and Gilead Sciences, two large biotech companies that pay dividends. Amgen's forward dividend yield tops 2.2%, while Gilead's is slightly below 2.1%, but Gilead has the lower payout ratio at 43.5% versus Amgen's 60.9%. Gilead also trades at 15.6 times forward earnings against Amgen's 16.7. Amgen's product sales rose 9% and it has 17 drugs on track to be blockbusters this year, versus 8% growth and eight drugs at Gilead. The author says Amgen fits income investors focused on yield and growth, while Gilead suits those prioritizing safety or value, and many investors could hold both.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Open a keyword to see other news on the same topic.
Related news
- 2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
The article examines Johnson & Johnson (JNJ) and Amgen (AMGN), two dividend stocks that have outperformed the market in 2026. For J&J, revenue and earnings beat expectations and guidance was slightly raised, but its medtech unit faces weaker Impella demand and a Class 1 recall in the U.S.; the article still sees long-term prospects intact, citing new drug launches, the OTTAVA surgical system, a proposed $5.5 billion talc settlement and a 64-year dividend increase streak. Amgen's second-quarter revenue rose 10% to $10.1 billion despite FDA moves to remove Tavneos and falling denosumab sales after losing exclusivity. The article says growth drivers such as Tezspire, Tepezza and the MariTide obesity candidate could offset these headwinds.
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months for Imfinzi alone, in patients whose cancer had not progressed after initial Imfinzi and chemotherapy. Nearly 80% of patients on the combination were alive at one year, versus 53% on Imfinzi alone. Imdelltra posted $288 million in second-quarter sales, up 115% year over year, after $627 million in global sales in 2025. Amgen said the results suggest earlier use of the drug could meaningfully alter the course of the disease, though the trial did not compare the combination with other first-line treatments.
- Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?
This comparison of Amgen (AMGN) and Bristol Myers Squibb (BMY) uses FY 2025 financials. Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion (net margin around 21%) and free cash flow near $8.1 billion; BMY posted revenue of about $48.2 billion, nearly flat, net income of about $7.1 billion (net margin about 14.6%) and free cash flow of about $12.8 billion. The article notes Amgen faces drug pricing pressure, an ongoing IRS tax dispute and biosimilar competition, while BMY depends heavily on Eliquis and faces generic competition and government pricing constraints. It concludes BMY trades at a significantly lower valuation than Amgen, though much of its expected difficulty may already be priced in.
- Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
The article compares three drugmakers: Biogen (BIIB), Amgen (AMGN) and Gilead (GILD). Biogen closed at $225.71 on October 9 after returning 30.5% over six months, Amgen closed at $414.87 (up 18.6%), and Gilead closed at $151.17 (up 8.8%). Gilead posted a net loss of more than $3 billion over the past year yet generated the most cash in the group and the highest return on assets at 14.09%, which the author attributes to accounting charges. Revenue grew roughly 10% at Gilead and Amgen versus 3.40% at Biogen, whose earnings fell 84.60% in the latest quarter. Biogen has the lowest forward P/E at 13.65 times, versus 15.29 for Gilead and 16.94 for Amgen, and the author sees Gilead as worth its small premium.
- Daughter of Nam A Bank Chairman appointed CEO of Ben Tre Pharmaceutical
Tran Ngo Minh Anh, born in 2002 and the daughter of Nam A Bank Chairman Tran Ngo Phuc Vu, has been appointed General Director of Ben Tre Pharmaceutical JSC (Bepharco, ticker DBT, HoSE) effective November 1, 2026. She became a board member and Deputy General Director on July 30, 2026, replacing Nguyen Khac Hanh, who resigned after just over three months in the role. She holds a finance degree from the University of Central Florida and worked at New Omni Bank in California, US, during 2024-2026, and she currently owns no DBT shares. DBT also approved a stock dividend issuance at a 7% ratio (100:7), equal to 1.53 million new shares, which would raise charter capital from VND 219.6 billion to nearly VND 235 billion once completed.
- What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
The article argues that rising interest rates could make the high dividend yields of pharmaceutical stocks such as Pfizer and AbbVie less appealing, since the 10-year U.S. Treasury yield serves as the benchmark for comparing income investments. The Federal Reserve raised rates by 25 basis points last month after a series of cuts in 2024 and 2025, and numerous economists expect further hikes. Pfizer, with a 5.7% dividend yield, has several top products approaching patent expiration and is in a slow reset phase, while AbbVie's 2.4% yield is supported by growth from Skyrizi and Rinvoq. The author expects rising rates to pressure Pfizer's stock more than AbbVie's, though he remains bullish on both companies.
Related markets
Latest news
- SpaceX, Meta, and other hyperscalers are dropping clues you should not ignore
The article argues investors should pay attention to capital-raising signals from SpaceX (SPCX), Meta (META) and other hyperscalers, even if the market has been slow to react. SpaceX has signaled it will need large amounts of capital for its space and AI ambitions, and some market participants estimate the figure could reach hundreds of billions of dollars. Large capital raises would add interest payments and execution pressure, increasing SpaceX's risk profile. Meta announced a new class of stock to fund its AI build-out, which JPMorgan said creates an overhang until the shares are issued. The article expects Meta will need more capital, likely from debt markets, and says the market has begun pricing these risks into both stocks.
- Trump says US could attack Iran 'as soon as tomorrow' or reach a major deal
US President Donald Trump said Washington is considering a strike on Iran that could come as early as tomorrow, while leaving open the possibility of a deal with Tehran. He said his goal is to prevent Iran from developing nuclear weapons in the long term, and argued that an earlier US campaign using B-2 bombers was not enough to ensure lasting results. Trump also said oil flows through the Strait of Hormuz had risen compared with before the conflict, without providing specific figures. Earlier, US envoy Tom Barrack said a strike could happen this weekend. The conflict between the US, Israel and Iran began in February and has spread across the Middle East, yet nearly nine months later the sides have not found a way to end the tensions.
- 3 AI Stocks That Can Beat the Nasdaq Composite in 2027
The article highlights three AI stocks that could outperform the Nasdaq Composite in 2027: Dell (DELL), Silicon Motion Technology (SIMO) and Maxlinear (MXL). Dell ended its fiscal Q2 2027 with a 95 billion USD backlog and 47 billion USD in revenue, and raised its full-year guidance, with its infrastructure segment revenue up 89%. Silicon Motion's second-quarter sales rose 127% year over year, and its Ferri & Boot Drive segment revenue grew roughly 1,700%. Maxlinear's AI infrastructure segment revenue surged 145%, and its Q3 forecast high end points to sales of 220 million USD.
- Which banks are offering the highest savings interest rates on October 25?
Based on rates listed at 35 banks on October 25, 2026, the highest 12-month savings rate is 7% per year, offered by MBV, PGBank, Sacombank, VCBNeo and VIB. For the 18-month term, VPBank leads at 7.4% per year, while MBV, Sacombank and VCBNeo list 7% per year. The four state-owned banks Agribank, BIDV, Vietcombank and VietinBank apply uniform rates: 4.75% per year for 3 months, 6.6% for 6 and 9 months, and 6.8% for 12 and 18 months. The article notes that actual rates may vary by time, deposit amount, deposit method and agreement with the bank.
- Here's the Price at Which I'd Buy Microsoft Stock
Microsoft closed at a record 543.45 USD on October 13 and trades near 530 USD, about 2% below that high. The stock trades at about 31 times fiscal 2026 adjusted earnings of 17.28 USD per share, after revenue rose 18% to 331.8 billion USD. The article says earnings growth is slowing as capital spending climbs, with capex expected around 175 billion USD in calendar 2026 and free cash flow down about 6% to roughly 67 billion USD. The author says he would consider buying near 465 USD, about 27 times trailing adjusted earnings, and would not buy at current levels. The fiscal first-quarter report due October 28 could shift that price.
- Colombia Delays US$3 . 3 Billion of Debt
Colombia has pushed back about US$3.3 billion of bond payments due in 2026 and 2027 by swapping peso Treasury bonds (TES) worth COP 10.3 trillion for longer-dated bonds, its second swap in three weeks. The Finance Ministry says payments due fall by about US$475 million in 2026 and US$2.8 billion in 2027, but the swap does not reduce what the state owes. The swap cost about US$148 million, or 4.5% of the amount exchanged. The article cites a projected 2027 deficit of 9.4% of GDP unless new measures are adopted. A third and final swap this year is scheduled for November 19, 2026, and S&P and Fitch rate Colombia below investment grade.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.